PT-141 Evidence Summary

Author: New Blue Health Clinical Content Team Published: March 9, 2026 Last reviewed: March 9, 2026

PT-141 (bremelanotide, brand name Vyleesi) is a melanocortin receptor agonist with a central nervous system mechanism that differs from vascular treatments like PDE5 inhibitors. The key evidence anchor is the FDA-approved Vyleesi indication for acquired, generalized hypoactive sexual desire disorder in premenopausal women, which is narrower than much of the broader consumer interest online.

Clinical Context

Melanocortin-pathway discussions focus on centrally mediated desire and arousal signaling rather than blood-flow mechanics or hormone replacement. That mechanism is clinically relevant, but it should not be used to overstate what has been proven across populations outside the FDA-approved female HSDD setting.

Key Studies

RECONNECT Phase 3 Trials

Pivotal phase 3 data supporting the FDA-approved bremelanotide indication in premenopausal women with acquired, generalized HSDD.

Central Mechanism Literature

Melanocortin-pathway literature explains why PT-141 discussions differ from blood-flow or hormone-based conversations, but mechanism alone does not broaden the approved indication.

Early Off-label Male Literature

Smaller early-stage studies in men are part of the off-label discussion, but they do not carry the same evidentiary weight as the FDA-approved female HSDD trials.

DailyMed Label Context (Vyleesi)

Official labeling is the clearest source for nausea frequency, blood-pressure warnings, and indication-aware safety framing.

Evidence Quality

High

The evidence for PT-141 is strong for the specific FDA-approved indication in premenopausal women with acquired, generalized HSDD. Once the conversation shifts into broader off-label use, the evidence becomes more limited and should be framed as such.

Limitations & Safety Framing

Nausea is common, blood-pressure effects matter, and timing questions can change tolerability and fit. The evidence is not equally strong across all populations that may ask about PT-141 online.

Blood pressure monitoring is recommended, especially in patients with cardiovascular history. Risk, contraindications, and monitoring should be reviewed with a licensed clinician. This content is educational and does not replace individualized medical advice.

Medical review & editorial standards

This page is educational content from the New Blue Health Clinical Content Team. It is reviewed under the New Blue Health Medical Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.

Start Your Visit